-
06:45:07 PM

RHHBY Stock News

03/20/23 2:00 AM
OTC : RHHBY
New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease Data confirm long-term efficacy and safety profile of Evrysdi in a broad range of people with
RHEA-AI
neutral
03/09/23 6:45 PM
OTC : RHHBY
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech';s Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted 11 to 2 in favor of Polivy ® in combination with Rituxan ® plus cyclophosphamide, doxorubicin and prednisone for the treatment of people with previously untreated diffuse large B-cell lymphoma. “Today’ s committee...
RHEA-AI
positive
03/09/23 6:45 PM
OTC : RHHBY
FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
U.S. FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 in favour of the clinical benefit of the phase III POLARIX study of Polivy in combination with R-CHP for people with previously untreated diffuse large B-cell lymphoma (DLBCL) This is the first t reatment in 20 years to show a significant
RHEA-AI
positive
03/06/23 1:00 AM
OTC : RHHBY
fda approval
Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo
The VENTANA PD-L1 (SP263) Assay helps determine which patients with non-small cell lung cancer (NSCLC) may be eligible for treatment with Libtayo monotherapy 1 based on the results of the Phase III EMPOWER-Lung 1 study. This additional approval will allow more patients with locally advanced and
RHEA-AI
very positive
03/06/23 1:00 AM
OTC : RHHBY, CHGCY
fda approval
Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo
Roche today announced that the U.S. Food and Drug Administration has approved the VENTANA PD-L1 Assay as a companion diagnostic to identify non-small cell lung cancer patients eligible for treatment with Libtayo ®, a PD-1 inhibitor therapy developed by Regeneron. More than 60 percent of patients diagnosed with NSCLC are diagnosed at locally advanced or...
RHEA-AI
very positive
02/28/23 1:00 AM
OTC : RHHBY, CHGCY
Roche joins forces with the U.S. Centers for Disease Control and Prevention to strengthen laboratory systems in the fight against the HIV and tuberculosis epidemics
Through the implementation of a public-private partnership, named "Lab Networks for Health," Roche and the CDC will seek to improve HIV and tuberculosis prevention, detection, and treatment outcomes in select countries of Africa, Eastern Europe, Central Asia, and the Western Hemisphere. Specifically, Roche and CDC intend to increase laboratory human resource...
RHEA-AI
neutral